Regulatory standard
USP <795> Nonsterile Compounding Overview
Scope; categories; facilities; documentation; BUD concepts; licensed-standard access; no copyrighted reproduction.
USP General Chapter 795 sets standards for compounding NONSTERILE preparations — creams, capsules, oral liquids, suppositories. Chapter 795 governs nonsterile compounding: identity and quality of ingredients, equipment, personnel training, documentation, and the assignment of beyond-use dates.
Key findings
- Chapter 795 governs nonsterile compounding: identity and quality of ingredients, equipment, personnel training, documentation, and the assignment of beyond-use dates.
- Beyond-use dating under Chapter 795 is category-based rather than tested per batch, and is substantially shorter than a manufacturer expiry derived from formal stability programmes.
- It is enforced through state boards of pharmacy, which adopt USP by reference. It is not directly an FDA rule for 503A pharmacies, which is a distinction that confuses many buyers.
- A 503B outsourcing facility is held to CGMP, a considerably more demanding standard than Chapter 795.
- Entity-specific compliance with this standard is not asserted on this page.
| Scope | Verification Pending |
|---|---|
| Categories | Verification Pending |
| Facilities | Verification Pending |
| Documentation | Verification Pending |
| Bud concepts | Verification Pending |
| Licensed-standard access | Verification Pending |
| Federal framework | License Verified FDA sources verified 2026-07-23 |
| Entity-specific data | Verification Pending |
What this standard actually requires
USP General Chapter 795 sets standards for compounding NONSTERILE preparations — creams, capsules, oral liquids, suppositories.
Chapter 795 governs nonsterile compounding: identity and quality of ingredients, equipment, personnel training, documentation, and the assignment of beyond-use dates.
Beyond-use dating under Chapter 795 is category-based rather than tested per batch, and is substantially shorter than a manufacturer expiry derived from formal stability programmes.
It is enforced through state boards of pharmacy, which adopt USP by reference. It is not directly an FDA rule for 503A pharmacies, which is a distinction that confuses many buyers.
A 503B outsourcing facility is held to CGMP, a considerably more demanding standard than Chapter 795.
What is established about scope?
For USP 795 compounding, scope is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where scope has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about categories?
For USP 795 compounding, categories is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where categories has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about facilities?
For USP 795 compounding, facilities is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where facilities has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about documentation?
For USP 795 compounding, documentation is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where documentation has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about bud concepts?
For USP 795 compounding, bud concepts is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where bud concepts has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What does this page establish?
It establishes the framework and the source map for USP 795 compounding, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.
What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.
What this means
- The framework governing USP 795 compounding is cited to FDA primary sources.
- The record holding each element of scope is named.
- Verification dates are published on every field so staleness is visible.
What this does not mean
- That any entity connected with USP 795 compounding is compliant or non-compliant.
- That the absence of a record indicates the absence of an issue.
- That this platform certifies or endorses any facility or preparation.
Status terms on this page follow the platform's published status vocabulary.
- No entity-specific record relating to USP 795 compounding has been verified at this snapshot.
- Scope may change without notice to this platform.
- Regulatory positions change through rulemaking, guidance, and enforcement action.
- Records held by different agencies may disagree; conflicts are published as conflicts.
Sources verified for this page — 10 sources
- FDA — Information for Outsourcing Facilitieschecked 2026-07-23
- FDA — Q&A: Outsourcing Facility Registrationchecked 2026-07-23
- FDA — Registered Outsourcing Facilitieschecked 2026-07-23
- FDA — Aligning Federal and State Regulation of Compounderschecked 2026-07-23
- FDA — Outsourcing Facility Feeschecked 2026-07-23
- FDA — Compounded Drug Products That Are Essentially Copieschecked 2026-07-23
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)checked 2026-07-23
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)checked 2026-07-23
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)checked 2026-07-23
- FDA — Outsourcing Facility Fees guidancechecked 2026-07-23
Why USP 795 compounding is hard to verify
Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.
First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.
That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.
| Structural feature | Consequence for verification | How this platform handles it |
|---|---|---|
| Split federal and state authority | No single register is complete for any entity | Both systems are named per field, and neither is presented as sufficient |
| Registration precedes inspection | A registration is not evidence of oversight | Registration and inspection are reported as separate facts |
| Records go stale silently | A citation without a date implies currency it may not have | Every field carries its own verification date |
| Observations are not findings | A Form 483 is frequently reported as a violation | Observations and final actions are stored and displayed separately |
| Resolved actions persist online | Closed matters get reported as current | Current and historical status are distinct states, never merged |
Related records in this section
Section hub: Regulatory standards · Methodology · Status definitions · Right to respond
Frequently asked questions
What does this page cover on USP 795 compounding?
Scope; categories; facilities; documentation; BUD concepts; licensed-standard access; no copyrighted reproduction.
What is established about scope?
Scope is tracked as part of USP 795 compounding. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about categories?
categories is tracked as part of USP 795 compounding. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about facilities?
facilities is tracked as part of USP 795 compounding. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
Which agency holds the record behind USP 795 compounding?
Federal registration and inspection records sit with FDA; licensure and discipline sit with the relevant state board of pharmacy. The two systems are separate and must both be checked.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.